Verge Genomics' CONVERGE Platform Nominated PIKfyve From ~1,000 ALS Tissue Samples and Derived the GPNMB Biomarker for Its Phase 1b Trial
Verge Genomics' CONVERGE 1.0 platform picked PIKfyve as an ALS target from a multi-omic analysis of nearly 1,000 patient and control tissue samples, and its PIKfyve gene network supplied GPNMB as the biomarker used to confirm target engagement and set dosing. The resulting drug, VRG50635, missed its efficacy endpoint in a 54-patient Phase 1b, exposing gaps in patient heterogeneity and blood-to-brain inference that Verge is addressing with generative models in CONVERGE 2.0.